Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Coronavirus: AVAT to partner with UNICEF in scaling up vaccine deliveries to African Union Member States Established by African leaders, AVAT has spearheaded African efforts on fair equitable access and distribution of vaccines

08/03/2021 | 08:12am EDT

Having secured access to up to 400 million doses of the J&J COVID-19 vaccine, the African Union (AU), African Vaccine Acquisition Trust (AVAT) and UNICEF are partnering to ensure the seamless procurement and delivery of vaccines to AU Member States. This partnership will help ramp up efforts to mitigate the impact of the pandemic as less than 2 per cent of people on the continent are fully vaccinated so far.

"We are building a platform for deeper collaboration that will pave the way to a more robust African response to the pandemic and move the continent towards recovery, leveraging the opportunities to strengthen health systems and support the manufacturing sector for job creation," said Dr. Vera Songwe, United Nations Under-Secretary-General and Executive Secretary of the Economic Commission for Africa.

"We are pleased to have UNICEF as a strategic partner in the delivery of these vaccines to our member states, as they are extremely experienced in handling and managing vaccines, and a strong and well-established relationship with all AU member states,"said Mr. Strive Masiyiwa, African Union Special Envoy.

Established by African leaders, AVAT has spearheaded African efforts on fair equitable access and distribution of vaccines, negotiating vaccine acquisition with pharmaceutical companies to at least 60 per cent of the African population with safe and efficacious vaccines to achieve "herd immunity" by 2022.

"Since the pandemic began, Africa CDC has worked with COVAX to ensure that African Union Member States get fair access to COVID-19 vaccines. At this critical moment where widespread vaccination is more urgent than ever, we must do all to vaccinate at least 60 per cent of the African population by 2022,"said Dr. John Nkengasong, Director of Africa CDC.

The procurement of these vaccine doses has been made possible with the support of the African Export-Import Bank (Afreximbank), which provided a US$2 billion Advance Procurement Commitment (APC) Guarantee facility to Johnson and Johnson on behalf of the AU Member States. The bank also made available direct financing to AU Member States which require funding to pay for the vaccines. In April 2021, Afreximbank made a down payment of US$330 million to Johnson and Johnson on behalf of the AU Member States, as part of the commitment under the Agreement.

"As the Financial and Transaction advisers to AVAT on the Johnson & Johnson Agreement, we are pleased to formally welcome UNICEF to the partnership and look forward to a fruitful collaboration for efficient delivery of vaccines to African countries," said Professor Benedict Oramah, President of Afreximbank.

Access to vaccines is the surest way out of the COVID-19-19 pandemic. Emerging new variants suggest that global recovery will remain elusive if Africa is left behind. Speed and scale in vaccine distribution are imperative for economic recovery. AVAT is pleased to be working with UNICEF to scale up the delivery of the acquired vaccines to countries to quickly increase the number of vaccinated people.

The AVAT and UNICEF partnership will also work to increase procurement and manufacturing on the continent as part of a broader strategy for sustainable health systems and job creation in Africa.

The pandemic has highlighted Africa’s pharmaceutical manufacturing vulnerabilities. Prior to the pandemic, the continent was only able to manufacture less than 2 per cent of the total medicines needed.

"Access to COVID-19 vaccines has been unjust and unfair, with people in Africa bearing the brunt of this inequality. This cannot continue," said UNICEF Executive Director Henrietta Fore. "UNICEF is a staunch partner of the African continent with a long history of delivering vaccines everywhere they are needed. We are pleased to join this partnership with the African Union and AVAT to maximize supply and access to vaccines."

The distribution of the J&J vaccines to countries through AVAT Advanced Purchase Agreement is expected to commence in August 2021.


Distributed by APO Group on behalf of United Nations Children’s Fund (UNICEF).

© African Press Organization, source Press Releases

All news about JOHNSON & JOHNSON
03:03pModerna Drops Ahead of FDA Committee COVID-19 Booster Decision
MT
01:21pCDC DATA : Moderna vaccine has edge in preventing COVID-19 hospitalizations
AQ
09:05aJOHNSON & JOHNSON : Slovenia starts mandatory vaccination for government workers
AQ
08:42aJOHNSON & JOHNSON : Janssen Presents Results from Phase 1b/2 NORSE Study in Pati..
PU
08:06aJOHNSON & JOHNSON : GSA Director Lauded for Luring More People to Get Covid-19 V..
AQ
08:00aJOHNSON & JOHNSON : Unit Janssen's Schizophrenia Drug Gets European Medicines Ag..
MT
06:06aJ&J's Janssen Gets CHMP Backing for Twice-Yearly Schizophrenia Treatment
DJ
09/16JOHNSON & JOHNSON : to Host Investor Conference Call on Third-Quarter Results
PR
09/16PFIZER : FDA Sees Current COVID-19 Vaccine Protocol as Still Effective Ahead of ..
MT
09/16Health Ministry - Four Covid-19 Vaccines Now Available in Sudan
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 407 M - -
Net income 2021 22 809 M - -
Net Debt 2021 1 880 M - -
P/E ratio 2021 19,1x
Yield 2021 2,52%
Capitalization 435 B 435 B -
EV / Sales 2021 4,63x
EV / Sales 2022 4,43x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 165,22 $
Average target price 185,83 $
Spread / Average Target 12,5%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.98%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.21.62%249 329
NOVO NORDISK A/S51.34%233 887
ELI LILLY AND COMPANY36.84%209 456
ABBVIE INC.0.87%190 996